Sirt1 protects against high-fat diet-induced metabolic damage
- PMID: 18599449
- PMCID: PMC2474520
- DOI: 10.1073/pnas.0802917105
Sirt1 protects against high-fat diet-induced metabolic damage
Abstract
The identification of new pharmacological approaches to effectively prevent, treat, and cure the metabolic syndrome is of crucial importance. Excessive exposure to dietary lipids causes inflammatory responses, deranges the homeostasis of cellular metabolism, and is believed to constitute a key initiator of the metabolic syndrome. Mammalian Sirt1 is a protein deacetylase that has been involved in resveratrol-mediated protection from high-fat diet-induced metabolic damage, but direct proof for the implication of Sirt1 has remained elusive. Here, we report that mice with moderate overexpression of Sirt1 under the control of its natural promoter exhibit fat mass gain similar to wild-type controls when exposed to a high-fat diet. Higher energy expenditure appears to be compensated by a parallel increase in food intake. Interestingly, transgenic Sirt1 mice under a high-fat diet show lower lipid-induced inflammation along with better glucose tolerance, and are almost entirely protected from hepatic steatosis. We present data indicating that such beneficial effects of Sirt1 are due to at least two mechanisms: induction of antioxidant proteins MnSOD and Nrf1, possibly via stimulation of PGC1alpha, and lower activation of proinflammatory cytokines, such as TNFalpha and IL-6, via down-modulation of NFkappaB activity. Together, these results provide direct proof of the protective potential of Sirt1 against the metabolic consequences of chronic exposure to a high-fat diet.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Impairment of energy sensors, SIRT1 and AMPK, in lipid induced inflamed adipocyte is regulated by Fetuin A.Cell Signal. 2018 Jan;42:67-76. doi: 10.1016/j.cellsig.2017.10.005. Epub 2017 Oct 10. Cell Signal. 2018. PMID: 29030114
-
Vascular Smooth Muscle Sirtuin-1 Protects Against Diet-Induced Aortic Stiffness.Hypertension. 2016 Sep;68(3):775-84. doi: 10.1161/HYPERTENSIONAHA.116.07622. Epub 2016 Jul 18. Hypertension. 2016. PMID: 27432859 Free PMC article.
-
Sirt1 mediates the effect of the heme oxygenase inducer, cobalt protoporphyrin, on ameliorating liver metabolic damage caused by a high-fat diet.J Hepatol. 2015 Sep;63(3):713-21. doi: 10.1016/j.jhep.2015.05.018. Epub 2015 May 27. J Hepatol. 2015. PMID: 26026874
-
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.Eur Heart J. 2015 Dec 21;36(48):3404-12. doi: 10.1093/eurheartj/ehv290. Epub 2015 Jun 25. Eur Heart J. 2015. PMID: 26112889 Free PMC article. Review.
-
SIRT1 and insulin resistance.Nat Rev Endocrinol. 2009 Jul;5(7):367-73. doi: 10.1038/nrendo.2009.101. Epub 2009 May 19. Nat Rev Endocrinol. 2009. PMID: 19455179 Review.
Cited by
-
Mouse promyelocytic leukemia zinc finger protein (PLZF) regulates hepatic lipid and glucose homeostasis dependent on SIRT1.Front Pharmacol. 2022 Nov 10;13:1039726. doi: 10.3389/fphar.2022.1039726. eCollection 2022. Front Pharmacol. 2022. PMID: 36438786 Free PMC article.
-
MicroRNA Regulation of SIRT1.Front Physiol. 2012 Mar 30;3:68. doi: 10.3389/fphys.2012.00068. eCollection 2012. Front Physiol. 2012. PMID: 22479251 Free PMC article.
-
Ca2+/calmodulin-dependent protein kinase kinase β phosphorylation of Sirtuin 1 in endothelium is atheroprotective.Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2420-7. doi: 10.1073/pnas.1309354110. Epub 2013 Jun 10. Proc Natl Acad Sci U S A. 2013. PMID: 23754392 Free PMC article.
-
A metabolic prosurvival role for PML in breast cancer.J Clin Invest. 2012 Sep;122(9):3088-100. doi: 10.1172/JCI62129. Epub 2012 Aug 13. J Clin Invest. 2012. PMID: 22886304 Free PMC article.
-
Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism.Vitam Horm. 2013;91:385-404. doi: 10.1016/B978-0-12-407766-9.00016-X. Vitam Horm. 2013. PMID: 23374725 Free PMC article. Review.
References
-
- Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev. 2006;27:779–793. - PubMed
-
- Cooke D, Bloom S. The obesity pipeline: Current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5:919–931. - PubMed
-
- Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132:2087–2102. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials